Last Price$175.8(3.8%)
Market Cap$14.5B
2.0%
Peers median - 1.2%
13.5%
Peers median - 20.1%
37.4%
Peers median - 37.7%
6.8%
Peers median - 8.4%
Competing with ICLR
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$14.5B | 6.4 | $329.2 87.3% undervalued | (47.1%) | $8,281.7M | $1,116.7M | 2.0% | 13.5% | 25.8% | 6.8% | 37.4% | |
$197.5B | 6.4 | $646.4 25.7% undervalued | (14.0%) | $42.9B | $7,267.0M | 0.1% | 16.9% | 41.5% | 7.9% | 63.0% | |
$148.7B | 6.1 | $163.9 20.3% overvalued | (18.3%) | $23.9B | $5,296.0M | (0.1%) | 22.2% | 59.5% | 5.9% | 32.3% | |
$35.7B | 7.1 | $220.4 48.3% overvalued | (22.2%) | $3,897.5M | $798.1M | 6.5% | 20.5% | 61.1% | 42.1% | 10.5% | |
$34.5B | 7.2 | $97.5 19.5% overvalued | (17.3%) | $6,533.0M | $1,409.0M | (3.0%) | 21.6% | 54.0% | 14.7% | 55.8% | |
$33.3B | 6.1 | $298.1 62.5% undervalued | (29.0%) | $15.4B | $2,114.0M | 2.5% | 13.7% | 31.4% | 9.0% | 24.6% | |
$26.7B | 6.9 | $842.1 32.3% overvalued | (4.2%) | $3,872.4M | $864.4M | 2.2% | 22.3% | 59.1% | 40.7% | (1,587.1%) | |
$22.9B | 6.6 | $233.9 38.2% overvalued | 7.1% | $2,958.4M | $619.6M | 0.1% | 20.9% | 58.2% | 19.7% | 93.1% | |
$18.9B | 6.0 | $345.6 105.5% undervalued | 32.7% | $9,872.0M | $909.0M | 6.7% | 9.2% | 32.4% | 7.9% | 100.4% | |
$18.0B | 6.0 | $88.7 36.7% overvalued | 56.8% | $1,696.9M | $69.2M | 56.7% | 4.1% | 60.3% | (39.5%) | 15.7% | |
$13.8B | 6.6 | $127.4 12.8% undervalued | 3.6% | $2,755.0M | $541.7M | 0.2% | 19.7% | 52.5% | 3.1% | 43.1% |
Compare ICLR Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
ICON Public Limited CompanyICLR
2.1x
2.0%
28.7%
9.6%
Median Peer Set
6.3x
1.2%
2.6%
15.6%
Agilent Technologies, Inc.A
5.6x
(4.7%)
5.2%
19.8%
Quest Diagnostics IncorporatedDGX
2.6x
6.7%
2.8%
8.8%
Danaher CorporationDHR
6.8x
(0.1%)
(17.9%)
16.3%
IDEXX Laboratories, Inc.IDXX
9.1x
6.5%
6.1%
22.8%
IQVIA Holdings Inc.IQV
2.1x
2.8%
2.4%
8.9%
Mettler-Toledo International Inc.MTD
7.4x
2.2%
12.7%
22.3%
Natera, Inc.NTRA
10.1x
56.7%
(59.5%)
(11.2%)
Revvity, Inc.RVTY
5.8x
0.2%
(58.6%)
9.8%
Thermo Fisher Scientific Inc.TMO
5.2x
0.1%
6.8%
14.8%
Waters CorporationWAT
8.2x
0.1%
(1.1%)
21.6%
Compare ICLR Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does ICON Public Limited Company (ICLR) revenue growth compare to peers and the industry?
ICON Public Limited Company (ICLR) revenue growth is 2.0%, compared to the peers' median of 1.2%.
2. How does ICON Public Limited Company (ICLR) Free Cash Flow (FCF) margin compare to peers and the industry?
ICON Public Limited Company (ICLR) FCF margin is 13.5%, compared to the peers' median of 20.1%.
3. How does ICON Public Limited Company (ICLR) Total Debt to Equity ratio compare to peers and the industry?
ICON Public Limited Company (ICLR) Total Debt to Equity ratio is 37.4%, compared to the peers' median of 37.7%.
4. How does ICON Public Limited Company (ICLR) ROIC (Return on Invested Capital) compare to peers and the industry?
ICON Public Limited Company (ICLR) ROIC is 6.8%, compared to the peers' median of 8.4%.